Evolocumab in STEMI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 166 participants.
Also called NCT06081803
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Sponsor
- Registry
-
NCT06081803
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06081803. Randomized; single masking; primary purpose treatment. Start 2020-12-05 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evolocumab in STEMI
- Acronym
- EVO-STEMI
- Condition
- ST Elevation Myocardial Infarction
- Intervention (Drug)
- Repatha®
- Lead sponsor
- Sejong General Hospital
- Collaborator
- Samsung Medical Center
- Collaborator
- National Health Insurance Service Ilsan Hospital
- Collaborator
- Chonnam National University Hospital
- Collaborator
- Daegu Catholic University Medical Center
- Collaborator
- Catholic University of Korea Eunpyeong St. Mary's Hospital
Record details
- Record id
cardio:ct-nct06081803- Content hash
a67157b341fd8aef018d244faa0fe52cb7c3b2ce62d3a7ab6085417b9cdef41a